Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04091048 · ClinicalTrials.gov registry record
Optimize PRO Study
A clinical trial, sponsored by Medtronic Cardiovascular.
- Completed
- Registry status
- 1,127
- Enrollment target
NCT04091048 is a clinical trial that has completed, run by Medtronic Cardiovascular. The registered enrollment target is 1,127 participants.
The verdict
NCT04091048 has completed, sponsored by Medtronic Cardiovascular.
- COMPLETED
- Registry status
- 1,127 participants
- Enrollment target
Study Summary
The purpose of this study is to collect clinical evidence on valve performance and procedural outcomes associated with an "optimized" TAVR care pathway and post-TAVR conduction disturbance pathway while using the Evolut™ PRO and Evolut™ PRO+ devices. The purpose of the addendum is to collect post-market clinical evidence on valve performance and procedural outcomes associated with the Evolut FX Device.
Interventions
- DEVICE Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,127 participants |
| Start Date | 2019-09-16 |
| Est. Completion | 2024-11-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04091048
The ClinicalTrials.gov registry entry for NCT04091048 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiovascular, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum) is the first listed.
NCT04091048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04091048 about?
NCT04091048 is a clinical study titled "Optimize PRO Study". The purpose of this study is to collect clinical evidence on valve performance and procedural outcomes associated with an "optimized" TAVR care pathway and post-TAVR conduction disturbance pathway while using the Evolut™ PRO and Evolut™ PRO+ devices. The purpose of the addendum is to collect post-m...
What is the current status of trial NCT04091048?
This trial is currently completed. The enrollment target is 1,127 participants. The study started on 2019-09-16. Estimated completion is 2024-11-13.
What interventions are being tested in trial NCT04091048?
The interventions under investigation include: Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum) (DEVICE).
Who is sponsoring clinical trial NCT04091048?
This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.